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Purpose of the study
It is not fully elucidated whether patients who receive
combination antiretroviral therapy (cART) can maintain
continued CD4+ T-cell count increases. Previous studies
suggested a plateau 2–4 years after treatment initiation.
We aimed to characterize the evolution of CD4+ T-cell
count in HIV-infected individuals receiving long-term
suppressive cART.
Methods
This is a retrospective study of patients receiving cART in
an HIV clinic cohort that maintained viral suppression
(HIV-RNA <400 copies/mL) for ≥5 years. We used linear
regression models to determine for each individual
whether CD4+ T-cell count continued to increase. Fur-
thermore, we estimated whether the slope of CD4+ T-cell
count for each individual became zero which we defined
as the CD4+ set-point. Using logistic regression methods,
we assessed factors associated with continued CD4+ T-cell
count rise and CD4+ set-point.
Summary of results
59 patients were included. The median baseline CD4+ T-
cell count was 238 (IQR, 120–360) cells/μL and the
median duration on ART was 7.6 (IQR, 5.9–9.3) years.
Independent predictors of continued CD4+ T-cell count
increase were baseline log10 HIV-RNA (OR 0.35, 95% CI
0.14–0.89; p = 0.026) and duration on ART (OR 0.65,
95% CI 0.47–0.91; p = 0.021). The CD4+ T-cell percent-
age at the start of ART was a significant predictor of time
to the CD4+ set point (HR 2.4, 95% CI 1.3–4.5; p < 0.01).
Patients who reached a CD4+ set-point had a significantly
higher baseline CD4+ T-cell percentage at the start of ART
compared to those who did not reach a CD4+ set-point;
20% vs. 13% (p < 0.01, 95% CI; 0.01–0.04). The median
T-cell count at the CD4+ set-point for individuals who
started ART with CD4+ T-cell count ≤200 cells/μL, 201–
350 cells/μL and >350 cells/μL was 616 (IQR, 579–789)
cells/μL, 719 (IQR, 580–899) cells/μL and 880 (696–
1057) cells/μL, respectively.
Conclusion
These findings suggest that CD4+ T-cell count continues
to increase in some patients after several years of cART.
Our results point to an advantage to commencing cART at
higher CD4+ T-cell strata.
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